Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Industry Discuss Regulatory Impacts Of Infusion Pump Safety Steps

This article was originally published in The Gray Sheet

Executive Summary

Imposing more stringent pre-market requirements on external infusion pumps may help reduce recalls, but could also slow market entry for safer pump designs, according to industry speakers at an FDA workshop
Advertisement

Related Content

Assurance Cases Are Slowing Down Infusion Pump Submissions, Branch Chief Says
Assurance Cases Are Slowing Down Infusion Pump Submissions, Branch Chief Says
Device Analysts See Tougher Mandates, More Recalls On Regulatory Horizon
Device Analysts See Tougher Mandates, More Recalls On Regulatory Horizon
Better Interfaces, User Testing Could Improve Infusion Pumps, Says FDA
Better Interfaces, User Testing Could Improve Infusion Pumps, Says FDA
FDA To Impose New Pre-market Requirements On Infusion Pump Makers
FDA To Impose New Pre-market Requirements On Infusion Pump Makers

Topics

Advertisement
UsernamePublicRestriction

Register

MT028938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel